© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

The company had planned to launch the generic version of Actos on August 17th, after a 2010 settlement with the Japanese drugmaker, Takeda Pharmaceuticals. Watson believes that the FDA improperly ...

David O. Watson, General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), recently sold shares of the company amounting to $101,103. The transaction, which occurred on January 22, 2025, ...

David O. Watson, the General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), recently sold a portion of his holdings ...

Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Sildenafil Tablets, 20mg. Sildenafil is the ...

Morgan Stanley Raises Price Target On Watson Pharmaceuticals To $78 Morgan Stanley Raises PT On Watson Pharmaceuticals To $78 Morgan Stanley Raises Price Target On Watson Pharmaceuticals To $78 ...